COYA
Coya Therapeutics, Inc. Common Stock
NASDAQ: COYA · HEALTHCARE · BIOTECHNOLOGY
$4.07
-4.46% today
Updated 2026-04-29
Market cap
$95.47M
P/E ratio
—
P/S ratio
12.02x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$4 – $8
Volume
0.1M
Coya Therapeutics, Inc. Common Stock (COYA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $6.00M | $3.55M | $7.95M |
| Revenue growth (YoY) | — | — | — | — | -40.8% | +123.6% |
| Cost of revenue | — | $16133.00 | $4.41M | $5.50M | $11.87M | $27361.00 |
| Gross profit | — | $-16133.00 | $-4.41M | $500679.00 | $-8.31M | $7.92M |
| Gross margin | — | — | — | 8.3% | -233.9% | 99.7% |
| R&D | $373454.00 | $2.54M | $4.94M | $6.04M | $11.89M | $16.73M |
| SG&A | $668700.00 | $2.31M | $4.85M | $7.83M | $8.89M | $11.45M |
| Operating income | $-1.04M | $-4.87M | $-9.81M | $-7.90M | $-17.25M | $-20.27M |
| Operating margin | — | — | — | -131.7% | -485.4% | -255.0% |
| EBITDA | $10435.00 | $-4.85M | $-9.26M | $-7.33M | $-17.20M | $-20.24M |
| EBITDA margin | — | — | — | -122.2% | -483.9% | -254.7% |
| EBIT | $-694219.00 | $-4.87M | $-9.29M | $-7.36M | $-17.22M | $-20.27M |
| Interest expense | $38976.00 | $21482.00 | $2.43M | — | — | — |
| Income tax | $-704.00 | $-21482.00 | $2.43M | $723852.00 | $-720287.00 | — |
| Effective tax rate | 0.1% | 0.4% | -24.8% | -10.0% | 4.6% | 0.0% |
| Net income | $-1.10M | $-4.89M | $-12.24M | $-7.99M | $-14.88M | $-21.23M |
| Net income growth (YoY) | — | -344.8% | -150.3% | +34.8% | -86.3% | -42.6% |
| Profit margin | — | — | — | -133.1% | -418.7% | -267.1% |